Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
COINPAYMENTS has named its founder Alex Alexandrov as Group CEO, marking a shift from his prior role as Chairman. The move coincides with multiple senior appointments intended to support an expansion strategy. The company reports processing more than $50 billion in transaction volume and serving over 250,000 merchants and one million wallet users s…
HII has promoted Greg Ennis to senior vice president and chief financial officer of its Mission Technologies division. Ennis will oversee financial planning, accounting, and cost control efforts, leveraging his 25 years of experience in government contracting to support the division's strategic growth initiatives. The move aims to strengthen financ…
Perspective Therapeutics announced that data from its novel radiopharmaceutical candidate lapemelanotide zapixetar ([212Pb]VMT01) for treating metastatic melanoma has been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting. Interim Phase I/IIa trial results highlight positive patient responses and good t…
Denmark's benchmark OMX Copenhagen 20 rose 1.03% at Friday's close, driven by strength in Oil & Gas, Consumer Goods and Chemicals sectors. Vestas Wind Systems, Zealand Pharma and AP Moeller - Maersk Class B were the session's top performers, while Genmab, Pandora and Coloplast Class B paced declines. Market breadth was positive, and external commod…
Frontdoor (FTDR) reported sustained revenue and margin strength in recent quarters, and evidence of membership growth returning is the catalyst that could re-rate the shares. At a market cap near $5.36B and free cash flow of $385M, valuation is reasonable for a high-margin, recurring-revenue model. This trade idea lays out an entry at $77.83, a sto…
MHVYF (Mitsubishi Heavy Ind New) trades on thin liquidity but shows constructive technicals and a growing short-interest profile that can accelerate a move higher if positive headlines arrive. We favor a buy for traders willing to accept OTC volatility, targeting $30 over 180 trading days with a $20 stop.
Biogen Inc. announced encouraging 52-week Phase 2 data from its ongoing AMETHYST Phase 2/3 study of litifilimab, an investigational therapy for cutaneous lupus erythematosus (CLE). Results show continued and rapid improvement in skin symptoms, with over 27% of patients achieving clear or almost clear skin, and a consistent safety profile. The FDA g…
RPM has the right playbook — diversified industrial coatings and sealants, consistent margin improvement and a long dividend streak — but the market has already baked in too much near-term perfection. With consensus growth modest, a negative earnings-ESP and stretched technicals relative to recent volatility, there is a high-probability, short-term…
Norway's stock market finished Friday with a slight gain as the Oslo OBX rose 0.14%. Strength in Healthcare Equipment & Services, Pharma Biotech & Life Sciences and Utilities helped push more names higher than lower. SalMar, Nordic Semiconductor and Gjensidige Forsikring were among the session's top performers, while Var Energi, TGS NOPEC and Kongs…
Forward Industries rallied in morning trading after disclosing a record quarterly rise in its Solana treasury and a preliminary, unaudited net asset value of about $870 million as of September 30, 2026. The company ended the fiscal fourth quarter with 8,501,298 SOL-equivalent tokens, adding 948,601 SOL during the period at an average cost of $83 pe…
President Donald Trump is expected to designate Jay Clayton, the current Director of National Intelligence who supervises 18 agencies, as his principal adviser on artificial intelligence, according to Reuters and an earlier CBS report. The White House has not formally confirmed the choice. The potential appointment marks a departure from the presid…
Alphabet is executing on AI and cloud, generating strong free cash flow while its valuation has pulled in. With a market cap north of $4.1 trillion but a P/E near 16.8 and a healthy balance sheet, this trade targets a recovery toward the 52-week highs as AI revenue catalysts and large hyperscaler deals drive upside over the next 180 trading days.
Riley Exploration Permian (REPX) offers a conventional oil & gas exposure in the Permian Basin with a $907M market cap, low leverage, positive free cash flow and a 3.9% yield. Valuation is compelling (P/E ~7.7, EV/EBITDA ~3.9); technicals are neutral and short interest is nontrivial. Trade idea: long REPX at $41.10, target $48.00, stop $36.00 for a…
CRISPR Therapeutics announced it will present Phase 1 clinical data of zugocabtagene geleucel (zugo-cel), a CRISPR/Cas9 gene-edited allogeneic CAR T cell therapy targeting CD19 for autoimmune diseases, at the American College of Rheumatology Convergence 2026. The therapy is under evaluation across rheumatologic, hematologic, and neurologic autoimmu…
The Baltic Exchange's dry bulk freight index rose modestly on Friday for a second consecutive session, propelled by gains in capesize vessel rates. Despite the daily uptick, the main index finished the week down 8.1%. Capesize earnings increased while panamax rates edged lower over the same period, leaving mixed signals across vessel classes.
Gold prices inched higher on Friday after weaker-than-expected U.S. jobs numbers raised the likelihood that the Federal Reserve will leave interest rates unchanged at its upcoming policy meeting. The metal remains on course for a second consecutive weekly loss, weighed by a strong U.S. dollar and elevated Treasury yields even as markets price in a …
Paramount Skydance Corp will drop its combined name and operate under the Skydance corporate identity once its $110 billion merger with Warner Bros. Discovery closes next week. CEO David Ellison says the change provides a unified parent company while maintaining the standalone prominence of Paramount and Warner Bros.; investors are focused on the o…
Northrop Grumman introduces FORTITUDE™, a patented multilayer gallium nitride chip technology that significantly advances data processing capabilities by delivering triple the power and twenty times better signal quality. Designed for satellites, radar, GPS, electronic warfare, and emerging 6G systems, FORTITUDE™ reduces component counts, weight, a…
Viking Holdings (VIK) pulled back from recent highs, creating a mid-term dip-buy opportunity. Solid Q2 results, high booking curves (96% for 2026) and fleet-driven revenue growth underpin margins that deserve a premium. Enter at $79.88, stop at $72.00 and target $112.00 over a 45-trading-day swing - asymmetric upside with a defendable stop.
Realty Income faces acute pressure from the bond market, but the business fundamentals - long-duration leases, tenant diversification, monthly payout discipline and active capital recycling - argue for a measured long trade. Targeting a rebound as rate volatility normalizes, this idea lays out entry, stop and target with clear timeframes and risk c…
SeaStar Medical announced that data evaluating the post-approval SAVE Registry results for their FDA-approved QUELIMMUNE (SCD-PED) device will be presented as a late-breaking poster at ASN Kidney Week 2026. The company focuses on treatments for critically ill patients with organ failure, especially pediatric acute kidney injury (AKI) due to sepsis.…
Meta's AI wins and strong FCF mask valuation and technical vulnerabilities. With a market cap near $1.87T, P/E around 27x, stretched technicals and rising short-volume in late September, we see a viable mid-term short opportunity. Entry $730.00, stop $757.00, target $660.00 over ~45 trading days.
Climb Bio, a clinical-stage biotechnology company, will present new clinical data for its investigational drugs CLYM116 and budoprutug targeting immune-mediated kidney diseases at the American Society of Nephrology Kidney Week 2026. The data includes preliminary Phase 1 results for CLYM116 in healthy volunteers and Phase 2 data for budoprutug in pr…
newcleo plc announced its first-half 2026 financial and operational results following its business combination and Nasdaq listing under ticker NWCL. The company raised approximately $247 million through the SPAC merger and PIPE financing, plus additional funds, totaling over $1 billion raised since inception. Key operational advances include major …
Vera Therapeutics announced that the final efficacy analysis of its ORIGIN 3 trial for TRUTAKNA (atacicept-vymj) in treating IgA nephropathy will be highlighted in a late-breaking oral presentation at ASN Kidney Week 2026. Additional interim data from the Phase 2 PIONEER trial in glomerular diseases will also be presented. TRUTAKNA is the first app…
